Edgar Filing: Wentworth Kerry - Form 4

| Wentworth Kerry Form 4 April 28, 2010 | | | | | | | | | |
|--|---|---|--|-------|---|--|---|---|--|
| Check this box if no longer subject to Section 16. | Wa | SECURITIES AND EXCHANGE COM Washington, D.C. 20549 CHANGES IN BENEFICIAL OWNERS SECURITIES | | | | | OMB Number: Expires: Estimated a burden hour | s per | |
| Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 5 obligations may continue. See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 | | | | | | | | | |
| (Print or Type Responses) | | | | | | | | | |
| 1. Name and Address of Reporting Po Wentworth Kerry | er Name and Ticker or Trading GENICS INC /DE/ [AGEN] | | | | 5. Relationship of Reporting Person(s) to Issuer | | | | |
| (Last) (First) (Mi | | 3. Date of Earliest Transaction (Check | | | | | all applicable) | | |
| C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900 | Day/Year) 2010 | | | | Director 10% Owner X Officer (give title Other (specify below) below) VP, Clin, Reg & Quality | | | | |
| (Street) | 4. If Amendment, Date Original Filed(Month/Day/Year) | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person | | | | |
| NEW YORK, NY 10010 | | | | | | Form filed by Me Person | ore than One Rep | oorting | |
| (City) (State) (Z | Zip) Tab | le I - Non-I | Derivative | Secui | rities Acqu | uired, Disposed of, | or Beneficiall | y Owned | |
| (Instr. 3) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transactio Code (Instr. 8) | 4. Securi on(A) or Di (Instr. 3, | spose | d of (D) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| Common | | Code V | | (D) | Price | | | | |
| Stock 04/26/2010 | | A <u>(1)</u> | 4,167 | А | \$ 1.19 | 144,704 | D | | |
| Common 04/26/2010 Stock | | S <u>(2)</u> | 4,165 | D | \$ 1.2146 | 140,539 | D | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Wentworth Kerry - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 4. Transact Code (Instr. 8) | 5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | ; | Date | 7. Tit Amou Unde: Secur (Instr | unt of rlying | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr |
|---|---|---|--------------------------------------|---|---------------------|--------------------|--|--|---|---|
| | | | Code V | ′ (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | | | | |
|---|---------------|-----------|-------------------------|-------|--|--|--|
| | Director | 10% Owner | Officer | Other | | | |
| Wentworth Kerry C/O ANTIGENICS INC. 162 FIFTH AVE., SUITE 900 NEW YORK, NY 10010 | | | VP, Clin, Reg & Quality | | | | |
| Signatures | | | | | | | |
| Christine M. Klaskin, by Power Attorney | of | 04/ | 28/2010 | | | | |
| **Signature of Reporting Person | | | Date | | | | |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents settlement of restricted stock awarded on January 26, 2010.

(2) Represents the sale of shares obtained from the vesting of restricted stock awarded on January 26, 2010. This sale has been made through a Rule 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.